Pronto Diagnostics Overview
Pronto Diagnostics develops, produces, and distributes genetic testing kits that provide rapid and accurate assays for detecting polymorphisms in DNA sequences associated with genetic diseases and predisposition to disease. The company's kits, which test for more than 35 different DNA variants, are suitable for both small-scale and large-scale clinical genetic analysis. The kits meet the highest international quality production standards and have all received the European CE mark. In the complete genotyping format of the Pronto system, each mutation site is tested in two wells of a 96-well microtiter plate. Every sample is separately and internally controlled for each mutation tested. Results are clearly determined visually as well as analyzed by a standard ELISA reader. Pronto Diagnostics performs all operating and commercial activities for Aferrix, a diagnostic start-up specializing in the analysis of plasma iron levels.
Latest News
growth-positive
Novolog acquires 75% of Pronto Diagnostics for about ILS 11 million
Novolog Group has acquired 75% of Pronto Diagnostics, a company that operates clinical laboratories for genetic sequencing diagnostics and other tests. The acquisition is valued at approximately ILS 11.1 million, with an additional contingent payment of up to ILS 4 million. The medical laboratory segment, particularly genetics laboratories, is experiencing significant growth and is crucial for disease diagnosis, prevention, and treatment. The acquisition of Pronto Diagnostics complements Novologs healthcare division and aligns with the activities of AMLs laboratory. The seller will retain the remaining 25% of shares and continue as Pronto Diagnostics CEO for a defined period. The transaction is subject to regulatory approvals.
Acquisition
growth-positive
MNG Laboratories, Pronto Diagnostics partner to offer clinical RNA sequencing services in Israel
MNG Laboratories has signed a Distribution Agreement with Pronto Diagnostics to exclusively market its complete line of Clinical RNA Sequencing Services in Israel. This partnership allows MNG to expand its neurogenetic testing portfolio to the global rare disease diagnostic market. The RNA sequencing services offered by MNG can provide a diagnosis for patients with muscle disorders that cannot be diagnosed by DNA sequencing alone. The testing can also determine the effect of variants of uncertain significance on transcription. Testing will be performed at MNGs accredited laboratory and a clinical report will be delivered in 2-4 weeks.
Partners
growth-positive
Pronto Diagnostics Plans to Integrate FDNA's Phenotypic Analysis Into Its Genetic Tests
Israeli molecular diagnostics firm Pronto Diagnostics has partnered with FDNA to combine their genetic tests with FDNAs Face2Gene phenotyping applications. This collaboration will improve the chances of making a diagnosis by integrating phenotypic data into genetic testing pipelines. Pronto Diagnostics is dedicated to bringing patients answers to complex health questions more effectively and efficiently.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 0 |
| Investors | 0 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | www.prontodiagnostics.com/en |
Locations
Kiryat Atidim, Tel Aviv-Yafo, Israel
Photos & Videos
2 item(s)
Pronto Diagnostics Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyTest Diagnostics & ScreeningTarget Customer
Healthcare & Life SciencesHealthcareProvidersLaboratoriesLife SciencesBiotechnologyCore Technology
BiologicalsGenesTags (10)
medical-technologiesdetectionbiotechnologygeneticslaboratoriesdiagnosticsmolecular-biologyacademiahealthcare-providersgenetic-disordersGeographic Markets
GlobalPronto Diagnostics Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Acquired
Funding stage
0
Total rounds
0
Investors
Public Offering / Exit
MNAEvent
Oct 2022
Undisclosed
Pronto Diagnostics Lifecycle
All Events
MNAEvent
Oct 2022
Undisclosed
Pronto Diagnostics News
3 articles
growth-positive
Novolog acquires 75% of Pronto Diagnostics for about ILS 11 million
Novolog Group has acquired 75% of Pronto Diagnostics, a company that operates clinical laboratories for genetic sequencing diagnostics and other tests. The acquisition is valued at approximately ILS 11.1 million, with an additional contingent payment of up to ILS 4 million. The medical laboratory segment, particularly genetics laboratories, is experiencing significant growth and is crucial for disease diagnosis, prevention, and treatment. The acquisition of Pronto Diagnostics complements Novologs healthcare division and aligns with the activities of AMLs laboratory. The seller will retain the remaining 25% of shares and continue as Pronto Diagnostics CEO for a defined period. The transaction is subject to regulatory approvals.
Acquisition
growth-positive
MNG Laboratories, Pronto Diagnostics partner to offer clinical RNA sequencing services in Israel
MNG Laboratories has signed a Distribution Agreement with Pronto Diagnostics to exclusively market its complete line of Clinical RNA Sequencing Services in Israel. This partnership allows MNG to expand its neurogenetic testing portfolio to the global rare disease diagnostic market. The RNA sequencing services offered by MNG can provide a diagnosis for patients with muscle disorders that cannot be diagnosed by DNA sequencing alone. The testing can also determine the effect of variants of uncertain significance on transcription. Testing will be performed at MNGs accredited laboratory and a clinical report will be delivered in 2-4 weeks.
Partners
growth-positive
Pronto Diagnostics Plans to Integrate FDNA's Phenotypic Analysis Into Its Genetic Tests
Israeli molecular diagnostics firm Pronto Diagnostics has partnered with FDNA to combine their genetic tests with FDNAs Face2Gene phenotyping applications. This collaboration will improve the chances of making a diagnosis by integrating phenotypic data into genetic testing pipelines. Pronto Diagnostics is dedicated to bringing patients answers to complex health questions more effectively and efficiently.
Partners
Pronto Diagnostics Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 21 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Pronto Diagnostics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | funding rounds, markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 513434480 |
| Crunchbase | pronto-diagnostics |
| Phone | +972732126155 |
| Creator | Arielle Smolin |
| Creator email | ari.smolin@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-08-18T00:00:00.000Z |
| Created | 2014-07-07T00:00:00.000Z |
| Status detail | Acquired by Novolog Group on Oct, 2022 |